Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

440 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation.
Hesdorffer C, Ayello J, Ward M, Kaubisch A, Vahdat L, Balmaceda C, Garrett T, Fetell M, Reiss R, Bank A, Antman K. Hesdorffer C, et al. Among authors: garrett t. J Clin Oncol. 1998 Jan;16(1):165-72. doi: 10.1200/JCO.1998.16.1.165. J Clin Oncol. 1998. PMID: 9440739 Clinical Trial.
Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.
Vahdat LT, Papadopoulos K, Balmaceda C, McGovern T, Dunleavy J, Kaufman E, Fung B, Garrett T, Savage D, Tiersten A, Ayello J, Bagiella E, Heitjan D, Antman K, Hesdorffer C. Vahdat LT, et al. Among authors: garrett t. Clin Cancer Res. 1998 Jul;4(7):1689-95. Clin Cancer Res. 1998. PMID: 9676843 Clinical Trial.
High-dose thiotepa and etoposide-based regimens with autologous hematopoietic support for high-risk or recurrent CNS tumors in children and adults.
Papadopoulos KP, Garvin JH, Fetell M, Vahdat LT, Garrett TJ, Savage DG, Balmaceda C, Bruce J, Sisti M, Isaacson S, De LaPaz R, Hawks R, Bagiella E, Antman KH, Hesdorffer CS. Papadopoulos KP, et al. Among authors: garrett tj. Bone Marrow Transplant. 1998 Oct;22(7):661-7. doi: 10.1038/sj.bmt.1701408. Bone Marrow Transplant. 1998. PMID: 9818693
Reduction of paclitaxel-induced peripheral neuropathy with glutamine.
Vahdat L, Papadopoulos K, Lange D, Leuin S, Kaufman E, Donovan D, Frederick D, Bagiella E, Tiersten A, Nichols G, Garrett T, Savage D, Antman K, Hesdorffer CS, Balmaceda C. Vahdat L, et al. Among authors: garrett t. Clin Cancer Res. 2001 May;7(5):1192-7. Clin Cancer Res. 2001. PMID: 11350883 Clinical Trial.
Systemic adjuvant therapy of breast cancer.
Garrett TJ, Vahdat LT, Kinne DW. Garrett TJ, et al. J Surg Oncol. 1997 Feb;64(2):167-72. doi: 10.1002/(sici)1096-9098(199702)64:2<167::aid-jso16>3.0.co;2-3. J Surg Oncol. 1997. PMID: 9047258 Review.
Gemcitabine for relapsed or resistant lymphoma.
Savage DG, Rule SA, Tighe M, Garrett TJ, Oster MW, Lee RT, Ruiz J, Heitjan D, Keohan ML, Flamm M, Johnson SA. Savage DG, et al. Among authors: garrett tj. Ann Oncol. 2000 May;11(5):595-7. doi: 10.1023/a:1008307528519. Ann Oncol. 2000. PMID: 10907954 Free article. Clinical Trial.
Reversible ocular toxicity related to tamoxifen therapy.
Ashford AR, Donev I, Tiwari RP, Garrett TJ. Ashford AR, et al. Among authors: garrett tj. Cancer. 1988 Jan 1;61(1):33-5. doi: 10.1002/1097-0142(19880101)61:1<33::aid-cncr2820610107>3.0.co;2-i. Cancer. 1988. PMID: 3334951
Neurologic aspects of cobalamin deficiency.
Healton EB, Savage DG, Brust JC, Garrett TJ, Lindenbaum J. Healton EB, et al. Among authors: garrett tj. Medicine (Baltimore). 1991 Jul;70(4):229-45. doi: 10.1097/00005792-199107000-00001. Medicine (Baltimore). 1991. PMID: 1648656
440 results